Virios Therapeutics, Inc.
VIRI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $15 | $3 | $2 | $4 |
| G&A Expenses | $1 | $1 | $2 | $9 |
| SG&A Expenses | $1 | $1 | $2 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16 | $4 | $4 | $12 |
| Operating Income | -$16 | -$4 | -$4 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | -$6 | -$0 |
| Pre-Tax Income | -$16 | -$4 | -$11 | -$12 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$16 | -$4 | -$12 | -$13 |
| % Margin | – | – | – | – |
| EPS | -8.2 | -1.99 | -8.45 | -12.35 |
| % Growth | -312.1% | 76.4% | 31.6% | – |
| EPS Diluted | -8.2 | -1.99 | -8.45 | -12.35 |
| Weighted Avg Shares Out | 2 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$16 | -$4 | -$4 | -$12 |
| % Margin | – | – | – | – |